Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery

Authors: Cheng-Che Tu, Po-Kuei Hsu, Ling-I Chien, Wan-Chen Liu, Chien-Sheng Huang, Chih-Cheng Hsieh, Han-Shui Hsu, Yu-Chung Wu

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Pathological response is an important marker for tumor aggressiveness in patients with esophageal squamous cell carcinoma (ESCC) who receive preoperative chemoradiation followed by esophagectomy. We aim to evaluate the prognostic value of histological factors after trimodality treatments.

Methods

91 patients who received preoperative chemoradiation followed by transthoracic esophagectomy between 2009 and 2014 were included. The pathological examination was reviewed. Overall survival and disease free survival were recorded. Survival analysis was performed using the Cox regression model, and the survival curves were compared by the log-rank test.

Results

Survival analysis showed lymphovascular invasion (LVI, hazard ratio [HR]: 2.009, p = 0.029), perineural invasion (PNI, HR: 2.226, p = 0.019), ypN stage (HR: 2.041, p = 0.019), extracapsular invasion (ECI, HR: 2.804, p = 0.003), and incomplete resection (HR: 1.897, p = 0.039) as unfavorable prognostic factors affecting overall survival (OS). Moreover, tumor regression grade (TRG, HR: 1.834, p = 0.038), LVI (HR: 1.975, p = 0.038), ECI (HR: 2.836, p = 0.003), and incomplete resection (HR: 2.254, p = 0.007) adversely affected disease-free survival (DFS). Prognostic classification based on poor primary tumor (TRG2/3, LVI(+), and PNI (+)), lymph node (ypN(+) and ECI(+)), and surgical (incomplete resection) factors significantly predicts OS (p = 0.013) and DFS (p = 0.017). However, the use of postoperative adjuvant therapy was not a significant prognostic factor even in medium- and high-risk ESCC patients who underwent trimodality treatments.

Conclusions

Histological factors, including primary tumor, lymph node, and surgical factors has high prognostic value for predicting outcomes in ESCC patients receiving preoperative chemoradiation followed by surgery.
Literature
2.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
3.
go back to reference Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM, Sussman MS, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138:1309–17.CrossRefPubMedPubMedCentral Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM, Sussman MS, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138:1309–17.CrossRefPubMedPubMedCentral
4.
go back to reference Dittrick GW, Weber JM, Shridhar R, Shridhar R, Hoffe S, Melis M, et al. Pathologic non responders after neoadjuvant chemoradiation for esophageal cancer demonstrated no survival benefit compared with patient treated with primary esophagectomy. Ann Surg Oncol. 2012;19:1678–84.CrossRefPubMed Dittrick GW, Weber JM, Shridhar R, Shridhar R, Hoffe S, Melis M, et al. Pathologic non responders after neoadjuvant chemoradiation for esophageal cancer demonstrated no survival benefit compared with patient treated with primary esophagectomy. Ann Surg Oncol. 2012;19:1678–84.CrossRefPubMed
5.
go back to reference Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - a propensity score matched analysis. Eur J Cancer. 2014;50:2950–7.CrossRefPubMed Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - a propensity score matched analysis. Eur J Cancer. 2014;50:2950–7.CrossRefPubMed
6.
go back to reference Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17:1159–67.CrossRefPubMed Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17:1159–67.CrossRefPubMed
7.
go back to reference Hölscher AH, Drebber U, Schmidt H, Bollschweiler E. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg. 2014;260:779–84.CrossRefPubMed Hölscher AH, Drebber U, Schmidt H, Bollschweiler E. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg. 2014;260:779–84.CrossRefPubMed
8.
go back to reference Hsu PK, Huang CS, Wu YC, Chou TY, Hsu WH. Open versus thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma. World J Surg. 2014;38:402–9.CrossRefPubMed Hsu PK, Huang CS, Wu YC, Chou TY, Hsu WH. Open versus thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma. World J Surg. 2014;38:402–9.CrossRefPubMed
9.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago: Springer, Inc.; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago: Springer, Inc.; 2010.
10.
go back to reference Washington K, Berlin J, Branton P, Burgart LJ Carter DK, Fitzgibbons P, et al. Protocol for the examination of specimens from patients with carcinoma of the esophagus. College of American Pathologists Cancer Protocols 2009;1–16 (available at http://www.cap.org/). Accessed 31 Dec 2016. Washington K, Berlin J, Branton P, Burgart LJ Carter DK, Fitzgibbons P, et al. Protocol for the examination of specimens from patients with carcinoma of the esophagus. College of American Pathologists Cancer Protocols 2009;1–16 (available at http://​www.​cap.​org/​). Accessed 31 Dec 2016.
11.
go back to reference Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983–90.CrossRefPubMed Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983–90.CrossRefPubMed
12.
go back to reference Nomura M, Shitara K, Kodaira T, Hatooka S, Mizota A, Kondoh C, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:946–52.CrossRefPubMed Nomura M, Shitara K, Kodaira T, Hatooka S, Mizota A, Kondoh C, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:946–52.CrossRefPubMed
13.
go back to reference Kim JY, Nelson RA, Kim J, Raz D. How well does pathologic stage predict survival for esophageal adenocarcinoma after neoadjuvant therapy? J Thorac Dis. 2015;7:734–9.PubMedPubMedCentral Kim JY, Nelson RA, Kim J, Raz D. How well does pathologic stage predict survival for esophageal adenocarcinoma after neoadjuvant therapy? J Thorac Dis. 2015;7:734–9.PubMedPubMedCentral
14.
go back to reference Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed Revision of the Esophageal Cancer Staging System to Accommodate Pathologic Response (pP) Following Preoperative Chemoradiation (CRT). Ann Surg. 2005;241:810–20.CrossRefPubMedPubMedCentral Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed Revision of the Esophageal Cancer Staging System to Accommodate Pathologic Response (pP) Following Preoperative Chemoradiation (CRT). Ann Surg. 2005;241:810–20.CrossRefPubMedPubMedCentral
15.
go back to reference Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87:392–8.CrossRefPubMedPubMedCentral Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87:392–8.CrossRefPubMedPubMedCentral
16.
go back to reference Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330.CrossRefPubMed Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330.CrossRefPubMed
17.
go back to reference Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34.CrossRefPubMed Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34.CrossRefPubMed
18.
go back to reference Chen JW, Xie JD, Ling YH, Li P, Yan SM, Xi SY, et al. The prognostic effect of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer. 2014;14:313.CrossRefPubMedPubMedCentral Chen JW, Xie JD, Ling YH, Li P, Yan SM, Xi SY, et al. The prognostic effect of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer. 2014;14:313.CrossRefPubMedPubMedCentral
19.
go back to reference D’Annoville T, D’Journo XB, Loundou A, Trousse D, Dahan L, Doddoli C, et al. Prognostic impact of the extracapsular lymph node involvement on disease-free survival according to the 7th edition of American Joint Committee on Cancer Staging System. Eur J Cardiothorac Surg. 2013;44:e207–11.CrossRefPubMed D’Annoville T, D’Journo XB, Loundou A, Trousse D, Dahan L, Doddoli C, et al. Prognostic impact of the extracapsular lymph node involvement on disease-free survival according to the 7th edition of American Joint Committee on Cancer Staging System. Eur J Cardiothorac Surg. 2013;44:e207–11.CrossRefPubMed
20.
go back to reference D’Journo XB, Avaro JP, Michelet P, Trousse D, Tasei AM, Dahan L, et al. Extracapsular lymph node involvement is a negative prognostic factor after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer. J Thorac Oncol. 2009;4:534–9.CrossRefPubMed D’Journo XB, Avaro JP, Michelet P, Trousse D, Tasei AM, Dahan L, et al. Extracapsular lymph node involvement is a negative prognostic factor after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer. J Thorac Oncol. 2009;4:534–9.CrossRefPubMed
21.
go back to reference Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, et al. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2010;139:387–94.CrossRefPubMed Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, et al. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2010;139:387–94.CrossRefPubMed
22.
go back to reference Hsu PK, Chen HS, Wu SC, Wang BY, Liu CY, Shih CH, et al. Impact of hospital volume on long-term survival after resection for oesophageal cancer: a population-based study in Taiwan. Eur J Cardiothorac Surg. 2014;46:e127–35.CrossRefPubMed Hsu PK, Chen HS, Wu SC, Wang BY, Liu CY, Shih CH, et al. Impact of hospital volume on long-term survival after resection for oesophageal cancer: a population-based study in Taiwan. Eur J Cardiothorac Surg. 2014;46:e127–35.CrossRefPubMed
Metadata
Title
Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery
Authors
Cheng-Che Tu
Po-Kuei Hsu
Ling-I Chien
Wan-Chen Liu
Chien-Sheng Huang
Chih-Cheng Hsieh
Han-Shui Hsu
Yu-Chung Wu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3063-5

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine